Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
What are incretins, and how will they influence the management of type 2 diabetes?Blonde L; Rosenstock J; Triplitt CJ Manag Care Pharm 2006[Sep]; 12 (7 Suppl A): S2-12; quiz S14-6OBJECTIVE: To review the pathophysiology of type 2 diabetes (T2DM), the role of incretins, the potential of incretin-based therapies to address unmet therapeutic needs in T2DM, and the potential impact this will have on the contribution of managed care pharmacy to diabetes therapy. SUMMARY: Diabetes, the fifth leading cause of death by disease in the United States, costs approximately $132 billion per year in direct and indirect medical expenses. According to the Centers for Disease Control and Prevention.s National Health and Nutrition Examination Survey, a majority of diabetes patients do not achieve target A1C levels with their current treatment regimens. Advances in understanding the pathophysiologic abnormalities underlying the metabolic dysfunctions associated with T2DM are leading to the development of new treatment approaches and new therapeutic classes of drugs. Novel incretin-based therapies currently available, and in late-stage development, are among those showing the greatest promise for addressing the unmet needs of traditional therapies.|*Adenosine Deaminase Inhibitors[MESH]|*Dipeptidyl-Peptidase IV Inhibitors[MESH]|Adenosine Deaminase/physiology[MESH]|Diabetes Mellitus, Type 2/*drug therapy/economics/physiopathology[MESH]|Dipeptidyl Peptidase 4/physiology[MESH]|Disease Management[MESH]|Drug Design[MESH]|Drugs, Investigational/pharmacology[MESH]|Glucagon-Like Peptide 1/*agonists/*analogs & derivatives/physiology[MESH]|Glycated Hemoglobin[MESH]|Glycoproteins/*antagonists & inhibitors/physiology[MESH]|Humans[MESH]|Hypoglycemic Agents/*pharmacology/therapeutic use[MESH]|Insulin Resistance[MESH]|Managed Care Programs[MESH]|Obesity[MESH]|Prevalence[MESH] |
